MYC and cancer: IL-6 facilitates the recruitment of T cells into the TME but also drives chronic inflammation in cancer, and its overexpression is seen as a prognostic indicator of poor outcomes for cancer patients because it drives tumor progression through the activation of the cell cycle regulator cyclin D1, the proto-oncogene c-Myc, and the master metabolic regulator mTOR complex 1 (mTORC1) (100).